Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSMD14 | O00487 | 4/20 | 1.00 |
| ▸ | COPS5 | Q92905 | 4/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.62 |
| ▸ | CCR1 | P32246 | 2/20 | 0.61 |
| ▸ | CCR5 | P51681 | 2/20 | 0.61 |
| ▸ | CCR8 | P51685 | 2/20 | 0.61 |
| ▸ | PARP1 | P09874 | 2/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.50 |
| ▸ | SLC40A1 | Q9NP59 | 6/20 | 0.47 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.39 |
| ▸ | NFKBIA | P25963 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7376462 | 0.80 | PSMD14 (0.67) | PSMD14COPS5KDM4ECCR1CCR5 | |
| SCHEMBL2850764 | 0.78 | PSMD14 (0.65) | PSMD14COPS5KDM4ECCR1CCR5 | |
| SCHEMBL22326604 | 0.78 | PSMD14 (0.64) | PSMD14COPS5KDM4ECCR1CCR5 | |
| SCHEMBL10238875 | 0.78 | PSMD14 (0.64) | PSMD14COPS5KDM4ECCR1CCR5 | |
| SCHEMBL29800848 | 0.77 | KDM4E (0.62) | PSMD14COPS5KDM4ECCR1CCR5 | |
| SCHEMBL26074213 | 0.77 | KDM4E (0.62) | PSMD14COPS5KDM4ECCR1CCR5 | |
| SCHEMBL6422325 | 0.77 | PSMD14 (0.62) | PSMD14COPS5KDM4ECCR1CCR5 | |
| SCHEMBL26314901 | 0.77 | KDM4E (0.62) | PSMD14COPS5KDM4ECCR1CCR5 | |
| SCHEMBL3718782 | 0.77 | KDM4E (0.62) | PSMD14COPS5KDM4ECCR1CCR5 | |
| SCHEMBL5540860 | 0.77 | PSMD14 (0.62) | PSMD14COPS5KDM4ECCR1CCR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10005735-B2 | Inhibitors of RPN11 | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2018-06-26 | — | — | US | disclosed |
| WO-2017031255-A1 | INHIBITORS OF RPN11 | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2017-02-23 | — | — | WO | disclosed |
| US-20170050931-A1 | INHIBITORS OF RPN11 | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2017-02-23 | — | — | US | disclosed |
| US-20170050931-A1 | INHIBITORS OF RPN11 | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2017-02-23 | — | — | US | disclosed |
| US-8399447-B2 | Metal triangulo compound and methods of using the same | NATIONAL UNIVERSITY OF SINGAPORE (SG) | 2013-03-19 | — | — | US | disclosed |
| US-20100209431-A1 | METAL TRIANGULO COMPOUND AND METHODS OF USING THE SAME | NATIONAL UNIVERSITY OF SINGAPORE | 2010-08-19 | — | — | US | disclosed |
| EP-2147005-A1 | METAL TRIANGULO COMPOUND AND METHODS OF USING THE SAME | National University of Singapore (SG) | 2010-01-27 | — | — | EP | disclosed |
| WO-2008127197-A1 | METAL TRIANGULO COMPOUND AND METHODS OF USING THE SAME | NATIONAL UNIVERSITY OF SINGAPORE (SG) | 2008-10-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100209431-A1 | METAL TRIANGULO COMPOUND AND METHODS OF USING THE SAME | CASP3, BAX, CASP7 | PSMD14 1825/4885COPS5 752/4885KDM4E 3090/4885 |
| US-20170050931-A1 | INHIBITORS OF RPN11 | POLR2A, RPP30, RPIA | PSMD14 418/4885COPS5 700/4885KDM4E 3279/4885 |
| US-10005735-B2 | Inhibitors of RPN11 | POLR2A, RPP30, RPIA | PSMD14 418/4885COPS5 700/4885KDM4E 3279/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.